
    
      Primary objective

        -  Main objective of phase I: To evaluate the acute toxicity of treatment with FOLFIRINOX 3
           - bevacizumab

        -  Main objective of phase II: To evaluate the efficacy of treatment with FOLFIRINOX 3 -
           bevacizumab in terms of objective response according to the RECIST criteria.

      Secondary objectives

        -  To evaluate the efficacy of treatment with FOLFIRINOX 3 - bevacizumab in terms of
           objective response according to the criteria of CHOI, progression-free survival (PFS)
           and overall survival (OS)

        -  To evaluate the late toxicity of treatment with FOLFIRINOX 3 - bevacizumab

        -  Evaluate the quality of life
    
  